Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7528637 | 0.87 | KDM4E (0.71) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL5807758 | 0.86 | KDM4E (0.49) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL2707530 | 0.86 | KDM4E (0.66) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL7878306 | 0.86 | KDM4E (0.57) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL7873424 | 0.86 | ADRA1A (0.54) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL7434506 | 0.86 | KDM4E (0.57) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL8047226 | 0.85 | KMT2A (0.56) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL6318031 | 0.84 | KDM4E (0.72) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL7875568 | 0.84 | KDM4E (0.55) | KDM4EGLAKMT2AMEN1NPC1 | |
| SCHEMBL7875557 | 0.84 | KDM4E (0.55) | KDM4EGLAKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113768936-B | Application of evodiamine derivative in preparation of medicine for treating superficial fungal infection | 南华大学 | 2023-04-14 | — | — | CN | disclosed |
| CN-113768936-A | Application of evodiamine derivative in preparation of medicine for treating superficial fungal infection | 南华大学 | 2021-12-10 | — | — | CN | disclosed |
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-07-11 | — | — | US | disclosed |
| WO-2002022576-A2 | 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6001831-A | Process for producing quinazoline derivatives | CLARIANT GMBH (DE) | 1999-12-14 | — | — | US | disclosed |
| EP-0847392-B1 | PROCESS FOR PRODUCING QUINAZOLINE DERIVATIVES | CLARIANT GMBH (DE) | 1999-12-08 | — | — | EP | disclosed |
| EP-0738258-B1 | PROCESS FOR PREPARING N-SUBSTITUTED GLYCINIC ACIDS OR GLYCINE ESTERS AND USE OF SAID PROCESS IN INDIGO SYNTHESIS | DSM FINE CHEM AUSTRIA GMBH (AT) | 1999-07-28 | — | — | EP | disclosed |
| CN-1194639-A | Quinazoline derivatives and their use as anti-inflammatory agents | CORIEN CO LTD (DE) | 1998-09-30 | — | — | CN | disclosed |
| EP-0640594-A1 | Hydantoin derivative as metalloprotease inhibitor | FUJIREBIO INC. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | MKI67, FLT4, IDO1 | KDM4E 1608/4885GLA 1576/4885KMT2A 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.